Nature's Sunshine Products (NATR) 10-Q 10 May 16 2016 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2016	Apr. 29, 2016
Document and Entity Information
Entity Registrant Name	NATURES SUNSHINE PRODUCTS INC
Entity Central Index Key	275,053
Document Type	10-Q
Document Period End Date	Mar. 31, 2016
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		18,718,910
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	Q1

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Current assets:
Cash and cash equivalents	$ 46,433	$ 41,420
Accounts receivable, net of allowance for doubtful accounts of $181 and $190, respectively	8,146	7,700
Investments available for sale	1,791	1,772
Inventories	41,570	38,495
Deferred income tax assets	4,795	5,021
Prepaid expenses and other	7,262	7,110
Total current assets	109,997	101,518
Property, plant and equipment, net	69,374	68,728
Investment securities - trading	1,199	1,044
Intangible assets, net	536	559
Deferred income tax assets	17,105	17,339
Other assets	12,264	11,332
Total assets	210,475	200,520
Current liabilities:
Accounts payable	8,658	6,341
Accrued volume incentives	17,313	14,913
Accrued liabilities	21,226	23,726
Deferred revenue	6,491	4,160
Revolving credit facility payable	7,531	2,696
Income taxes payable	1,019	1,300
Total current liabilities	62,238	53,136
Liability related to unrecognized tax benefits	7,777	7,809
Deferred compensation payable	1,199	1,044
Other liabilities	2,370	2,266
Total liabilities	$ 73,584	$ 64,255
Commitments and contingencies
Shareholders’ equity:
Common stock, no par value, 50,000 shares authorized, 18,719 and 18,588 shares issued and outstanding, respectively	$ 127,442	$ 126,670
Retained earnings	18,285	18,088
Noncontrolling interests	2,470	2,750
Accumulated other comprehensive loss	(11,306)	(11,243)
Total shareholders’ equity	136,891	136,265
Total liabilities and shareholders' equity	$ 210,475	$ 200,520

CONDENSED CONSOLIDATED BALANCE3

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Statement of Financial Position [Abstract]
Accounts receivable, allowance for doubtful accounts	$ 181	$ 190
Common stock, par value (in dollars per share)
Common stock, shares authorized (in shares)	50,000,000	50,000,000
Common stock, shares issued (in shares)	18,719,000	18,588,000
Common stock, shares outstanding (in shares)	18,719,000	18,588,000

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Income Statement [Abstract]
Net sales revenue	$ 82,402	$ 83,878
Cost of sales	(22,020)	(21,881)
Gross profit	60,382	61,997
Operating expenses:
Volume incentives	29,877	30,337
Selling, general and administrative	28,385	26,330
Operating income	2,120	5,330
Other income (loss), net	1,559	(318)
Income before provision for income taxes	3,679	5,012
Provision for income taxes	1,890	809
Net income from continuing operations	1,789	4,203
Income from discontinued operations	0	1,312
Net income	1,789	5,515
Net loss attributable to noncontrolling interests	(280)	(152)
Net income attributable to common shareholders	$ 2,069	$ 5,667
Basic earnings per share attributable to common shareholders:
Net income from continuing operations (in dollars per share)	$ 0.11	$ 0.23
Income (loss) from discontinued operations (in dollars per share)	0	0.07
Net income attributable to common shareholders (in dollars per share)	0.11	0.30
Diluted earnings per share attributable to common shareholders:
Net income from continuing operations (in dollars per share)	0.11	0.23
Income from discontinued operations (in dollars per share)	0	0.07
Net income attributable to common shareholders (in dollars per share)	$ 0.11	$ 0.30
Weighted average basic common shares outstanding (in shares)	18,694	18,621
Weighted average diluted common shares outstanding (in shares)	19,130	19,192
Dividends declared per common share (in dollars per share)	$ 0.10	$ 0.10

CONDENSED CONSOLIDATED STATEME5

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Statement of Comprehensive Income [Abstract]
Net income	$ 1,789	$ 5,515
Foreign currency translation loss (net of tax)	(75)	(21)
Net unrealized gains on investment securities (net of tax)	12	22
Total comprehensive income	$ 1,726	$ 5,516

CONDENSED CONSOLIDATED STATEME6

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDERS' EQUITY - 3 months ended Mar. 31, 2016 - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock	Retained Earnings	Noncontrolling Interest	Accumulated Other Comprehensive Income (Loss)
Balance at Dec. 31, 2015	$ 136,265	$ 126,670	$ 18,088	$ 2,750	$ (11,243)
Balance (in shares) at Dec. 31, 2015	18,588	18,588
Increase (Decrease) in Shareholders' Equity
Share-based compensation expense	$ 882	$ 882
Shares issued from the exercise of stock options and vesting of restricted stock units, net of shares exchanged for withholding tax	(110)	$ (110)
Shares issued from the exercise of stock options and vesting of restricted stock units, net of shares exchanged for withholding tax (in shares)		131
Cash dividends ($0.10 per share)	(1,872)		(1,872)
Net income	1,789		2,069	(280)
Other comprehensive loss	(63)				(63)
Balance at Mar. 31, 2016	$ 136,891	$ 127,442	$ 18,285	$ 2,470	$ (11,306)
Balance (in shares) at Mar. 31, 2016	18,719	18,719

CONDENSED CONSOLIDATED STATEME7

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDERS' EQUITY (Parenthetical)	3 Months Ended
	Mar. 31, 2016$ / shares
Statement of Stockholders' Equity [Abstract]
Cash dividends (in dollars per share)	$ 0.10

CONDENSED CONSOLIDATED STATEME8

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income	$ 1,789	$ 5,515
Adjustments to reconcile net income to net cash provided by operating activities:
Provision for doubtful accounts	62	30
Depreciation and amortization	1,170	996
Share-based compensation expense	882	1,339
Tax benefit from the exercise of stock options	0	(52)
(Gain) loss on sale of property and equipment	68	(1,312)
Deferred income taxes	589	50
Purchase of trading investment securities	(177)	(112)
Proceeds from sale of trading investment securities	29	55
Realized and unrealized gains (losses) on investments	(25)	(46)
Foreign exchange (gains) losses	(913)	351
Changes in assets and liabilities:
Accounts receivable	(432)	(1,411)
Inventories	(2,695)	(1,989)
Prepaid expenses and other current assets	(107)	(1,837)
Other assets	(792)	74
Accounts payable	2,607	3,010
Accrued volume incentives	2,152	1,539
Accrued liabilities	(3,433)	(6,707)
Deferred revenue	2,331	(461)
Income taxes payable	(364)	(268)
Liability related to unrecognized tax benefits	(34)	230
Deferred compensation payable	155	80
Net cash provided by (used in) operating activities	2,862	(926)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of property, plant and equipment	(1,312)	(6,019)
Proceeds from sale of property, plant and equipment	14	1,312
Purchase of investments available for sale	0	(15)
Net cash used in investing activities	(1,298)	(4,722)
CASH FLOWS FROM FINANCING ACTIVITIES:
Payments of cash dividends	(1,872)	(1,865)
Net borrowings on revolving credit facility	4,835	348
Net proceeds from the exercise of stock options	59	1,640
Payment of withholding taxes related to the vesting of restricted stock units	(169)	0
Tax benefit from stock option exercise	0	52
Repurchase of common stock	0	(2,857)
Net cash provided by (used in) financing activities	2,853	(2,682)
Effect of exchange rates on cash and cash equivalents	596	(304)
Net increase (decrease) in cash and cash equivalents	5,013	(8,634)
Cash and cash equivalents at the beginning of the period	41,420	58,699
Cash and cash equivalents at the end of the period	46,433	50,065
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Cash paid for income taxes	1,474	2,608
Cash paid for interest	$ 20	$ 25

Basis of Presentation

Basis of Presentation	3 Months Ended
	Mar. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	Basis of Presentation Nature’s Sunshine Products, Inc., together with its subsidiaries (hereinafter referred to collectively as the “Company”), is a natural health and wellness company primarily engaged in the manufacturing and direct selling of nutritional and personal care products. The Company is a Utah corporation with its principal place of business in Lehi, Utah, and sells its products to a sales force of independent Managers and Distributors who use the products themselves or resell them to other independent Distributors or consumers. The formulation, manufacturing, packaging, labeling, advertising, distribution and sale of each of the Company’s major product groups are subject to regulation by one or more governmental agencies. The Company markets its products in Australia, Austria, Belarus, Canada, Colombia, Costa Rica, the Czech Republic, Denmark, the Dominican Republic, Ecuador, El Salvador, Finland, Germany, Guatemala, Honduras, Hong Kong, Iceland, Indonesia, Ireland, Italy, Japan, Kazakhstan, Latvia, Lithuania, Malaysia, Mexico, Moldova, Mongolia, the Netherlands, New Zealand, Nicaragua, Norway, Panama, the Philippines, Poland, Russia, Singapore, Slovenia, South Korea, Spain, Sweden, Taiwan, Thailand, Ukraine, the United Kingdom, and the United States. The Company also markets its products through a wholesale model to Argentina, Australia, Chile, Israel, New Zealand, Norway, Peru, Portugal, Spain and the United Kingdom. Principles of Consolidation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. The unaudited condensed consolidated financial statements include the accounts of the Company and its subsidiaries. All significant intercompany accounts and transactions are eliminated in consolidation. In the opinion of management, the accompanying unaudited condensed consolidated financial statements contain all adjustments (consisting of normal recurring accruals), considered necessary for a fair presentation of the Company’s financial information as of March 31, 2016 , and for the three-month periods ended March 31, 2016 and 2015 . The results of operations of any interim period are not necessarily indicative of the results of operations to be expected for the fiscal year ending December 31, 2016 . It is suggested that these condensed consolidated financial statements be read in conjunction with the consolidated financial statements and the notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2015 . Classification of Belarus as a Highly Inflationary Economy and Devaluation of Its Currency Since June 30, 2012, Belarus has been designated as a highly inflationary economy. The U.S. dollar is the Company’s functional currency for this market. As a result, there were no resulting gains or losses from a re-measurement of the financial statements using official rates of the Company’s Belarusian subsidiary. However, as a result of the weakening of the Belarusian ruble, the purchasing power of the Company’s independent Distributors in this market is reduced. During the three months ended March 31, 2016 and 2015 , the Company’s Belarusian subsidiary’s net sales revenue represented approximately 1.6 percent and 2.1 percent of consolidated net sales revenue, respectively. Restructuring Related Activities During 2015 , the Company announced a restructuring plan that has been substantially completed. Of the restructuring costs incurred during the year ended December 2015 , $0.1 million of severance costs and $0.1 million of other exit costs remained payable as of March 31, 2016 and $0.6 million of severance costs and $0.2 million of other exit costs remained payable as of December 31, 2015 . There were no restructuring costs incurred during the three months ended March 31, 2016 or 2015 , respectively. Recent Accounting Pronouncements In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09 Revenue from Contracts with Customers (Topic 606). This update requires an entity to recognize revenue to depict the transfer of promised goods and services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods and services. As such, this update affects an entity that either enters into contracts with customers or transfers goods and services or enters into contracts for the transfer of nonfinancial assets unless those contracts are within the scope of other standards. This update will supersede the revenue recognition requirements in Topic 605, Revenue Recognition, and most industry-specific guidance, and creates a Topic 606. In March 2016, the FASB issued ASU 2016-08, Revenue from Contracts with Customers - Principal versus Agent Considerations (Reporting Revenue Gross versus Net) , which further clarifies the implementation guidance on principal versus agent considerations contained in ASU 2014-09. In April 2016, the FASB issued ASU 2016-08, Revenue from Contracts with Customers - Identifying Performance Obligations and Licensing , which further clarifies the implementation guidance relating to identifying performance obligations and the licensing implementation guidance. These standards, pursuant to ASU No. 2015-14, Revenue from Contracts with Customers - Deferral of the Effective Date issued by the FASB in August 2015, will be effective for the Company in the first quarter of 2018. The adoption of this ASU is not expected to have a material impact on the Company’s results of operations, consolidated financial statements and footnote disclosures.” In August 2014, the FASB issued ASU No. 2014-15, Presentation of Financial Statements: "Going Concern" (Subtopic 205-40). The purpose of this ASU is to incorporate into U.S. GAAP management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern within one year after the date that the financial statements are issued, and to provide related footnote disclosures. This update is effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early application is permitted. The adoption of this ASU is not expected to have a material impact on the Company’s results of operations, consolidated financial statements and footnote disclosures. In July 2015, the FASB issued ASU No. 2015-11, Inventory (Topic 330): “Simplifying the Measurement of Inventory.” This update specifies that inventory should be subsequently measured at the lower of cost or net realizable value, which is the ordinary selling price less any completion, transportation and disposal costs. However, the ASU does not apply to inventory measured using the last-in-first-out or retail methods. This update is effective for interim and annual periods beginning after December 15, 2016. Adoption of the ASU is prospective. The adoption of this ASU is not expected to have a material impact on the Company’s results of operations, consolidated financial statements and footnote disclosures. In November 2015, the FASB issued ASU 2015-17, Income Taxes (Topic 740): "Balance Sheet Classification of Deferred Taxes." This guidance requires that entities with a classified statement of financial position present all deferred tax assets and liabilities as noncurrent. This update is effective for annual and interim periods for fiscal years beginning after December 15, 2016, which will require the Company to adopt the new guidance in the first quarter of fiscal 2017. Early adoption is permitted for financial statements that have not been previously issued and may be applied on either a prospective or retrospective basis. The adoption of this ASU is not expected to have a material impact on the Company’s results of operations, consolidated financial statements and footnote disclosures. In January 2016, the FASB issued ASU No. 2016-01, Financial Instruments - Overall (Subtopic 825-10): "Recognition and Measurement of Financial Assets and Financial Liabilities." This update amends the guidance in U.S. GAAP on the classification and measurement of financial instruments. Although the ASU retains many current requirements, it significantly revises an entity’s accounting related to (1) the classification and measurement of investments in equity securities and (2) the presentation of certain fair value changes for financial liabilities measured at fair value. The ASU also amends certain disclosure requirements associated with the fair value of financial instruments. This update is effective for interim and annual periods beginning after December 15, 2017. The adoption of this ASU is not expected to have a material impact on the Company’s results of operations, consolidated financial statements and footnote disclosures. In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842): "Accounting for Leases." This update specifies that lessees should recognize assets and liabilities arising from all leases, except for leases with a lease term of 12 months or less. The recognition, measurement, and presentation of expenses and cash flows arising from a lease by a lessee will largely remain unchanged and continue to depend on its classification as a finance or operating lease. For public companies, the ASU will be effective for annual periods beginning after December 15, 2018 with early adoption permitted. The adoption of this ASU is not expected to have a material impact on the Company’s results of operations or footnote disclosures; however, it is expected to gross-up the consolidated balance sheet. In March 2016, the FASB issued ASU 2016-09, Compensation - Stock Compensation (Topic 718): "Improvements to Employee Share-Based Payment Accounting". The amendments are effective for public companies for annual periods beginning after December 15, 2016, and interim periods within those annual periods. Several aspects of the accounting for share-based payment award transactions are simplified, including: (a) income tax consequences; (b) classification of awards as either equity or liabilities; and (c) classification on the statement of cash flows. The Company is currently in the process of evaluating the impact of the adoption on its financial statements.

Discontinued Operations

Discontinued Operations	3 Months Ended
	Mar. 31, 2016
Discontinued Operations and Disposal Groups [Abstract]
Discontinued Operations	Discontinued Operations In November 2014, the Company ceased its operations in Venezuela due to the difficulties and uncertainties related to import controls, difficulties associated with repatriating cash and high inflation. This market was part of the Company’s NSP Americas segment and all of the income from discontinued operations is attributable to the common shareholders of the Company. The following table summarizes the operating results of the Company’s discontinued operations (dollar amounts in thousands): March 31, March 31, Net sales revenue $ — $ — Income before income tax provision $ — $ 1,312 Income tax provision — — Income from discontinued operations $ — $ 1,312 During the three months ended March 31, 2015 , the Company received $1.3 million in net proceeds from the sales of its fixed assets in Venezuela, which is included in the results from discontinued operations.

Inventories

Inventories	3 Months Ended
	Mar. 31, 2016
Inventory Disclosure [Abstract]
Inventories	Inventories The composition of inventories is as follows (dollar amounts in thousands): March 31, December 31, Raw materials $ 14,183 $ 13,351 Work in progress 758 789 Finished goods 26,629 24,355 Total inventory $ 41,570 $ 38,495

Investments

Investments	3 Months Ended
	Mar. 31, 2016
Investments, Debt and Equity Securities [Abstract]
Investments	Investments The amortized cost and estimated fair values of available-for-sale securities by balance sheet classification are as follows (dollar amounts in thousands): As of March 31, 2016 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value U.S. government securities funds $ 1,794 $ — $ (3 ) $ 1,791 Total short-term investment securities $ 1,794 $ — $ (3 ) $ 1,791 As of December 31, 2015 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value U.S. government securities funds $ 1,794 $ — $ (22 ) $ 1,772 Total short-term investment securities $ 1,794 $ — $ (22 ) $ 1,772 There were no proceeds from the sales of available-for-sale securities during the three-month periods ended March 31, 2016 and 2015 . The Company’s trading securities portfolio totaled $1.2 million at March 31, 2016 , and $1.0 million at December 31, 2015 , and generated gains of $7,000 and $23,000 for the three months ended March 31, 2016 and 2015 , respectively. As of March 31, 2016 and December 31, 2015 , the Company had unrealized losses of $3,000 and $22,000 , respectively, in its U.S. government securities funds. There were no securities that were in a loss position for more than 12 months.

Revolving Credit Facility

Revolving Credit Facility	3 Months Ended
	Mar. 31, 2016
Debt Disclosure [Abstract]
Revolving Credit Facility	Revolving Credit Facility The Company’s revolving credit agreement with Wells Fargo Bank, N.A., permits the Company to borrow up to $25.0 million through September 1, 2017, bearing interest at LIBOR plus 1.25 percent ( 1.75 percent as of March 31, 2016 and December 31, 2015 ). The Company must pay an annual commitment fee of 0.25 percent on the unused portion of the commitment. Currently, the revolving credit agreement matures on September 1, 2017. The Company settles its net borrowings under the revolving credit agreement daily, and as a result, has classified its outstanding borrowings as current on its condensed consolidated balance sheet as of March 31, 2016 . At March 31, 2016 and December 31, 2015 , the outstanding balance under the revolving credit agreement was $7.5 million and $2.7 million , respectively. The revolving credit agreement contains restrictions on leverage, minimum net income, and consecutive quarterly net losses. In addition, the agreement restricts capital expenditures, lease expenditures, other indebtedness, liens on assets, guaranties, loans and advances, and the merger, consolidation and the transfer of assets except in the ordinary course of business. The Company remains in compliance with these debt covenants as of March 31, 2016 .

Net Income Per Share

Net Income Per Share	3 Months Ended
	Mar. 31, 2016
Earnings Per Share [Abstract]
Net Income Per Share	Net Income Per Share Basic net income per common share (“Basic EPS”), is computed by dividing net income by the weighted average number of common shares outstanding during the period. Diluted net income per common share (“Diluted EPS”) reflects the potential dilution that could occur if stock options or other contracts to issue common stock were exercised or converted into common stock. The computation of Diluted EPS does not assume exercise or conversion of securities that would have an anti-dilutive effect on net income per common share. Following is a reconciliation of the numerator and denominator of Basic EPS to the numerator and denominator of Diluted EPS for the three months ended March 31, 2016 and 2015 (dollar and share amounts in thousands, except for per share information): Three Months Ended 2016 2015 Net income attributable to common shareholders: Net income from continued operations $ 2,069 $ 4,355 Income from discontinued operations $ — $ 1,312 Net income $ 2,069 $ 5,667 Basic weighted average shares outstanding 18,694 18,621 Basic earnings per share attributable to common shareholders: Net income from continued operations $ 0.11 $ 0.23 Income from discontinued operations $ — $ 0.07 Net income $ 0.11 $ 0.30 Diluted shares outstanding Basic weighted-average shares outstanding 18,694 18,621 Stock-based awards 436 571 Diluted weighted-average shares outstanding 19,130 19,192 Diluted earnings per share attributable to common shareholders: Net income from continued operations $ 0.11 $ 0.23 Income from discontinued operations $ — $ 0.07 Net income $ 0.11 $ 0.30 Potentially dilutive shares excluded from diluted-per-share amounts: Stock options 86 399 Potentially anti-dilutive shares excluded from diluted-per-share amounts: Stock options 1,454 733 Potentially dilutive shares excluded from diluted-per-share amounts include performance-based options to purchase shares of common stock for which certain earnings metrics have not been achieved. Potentially anti-dilutive shares excluded from diluted-per-share amounts include both non-qualified stock options and unearned performance-based options to purchase shares of common stock with exercise prices greater than the weighted-average share price during the period and shares that would be anti-dilutive to the computation of diluted net income per share for each of the years presented.

Capital Transactions

Capital Transactions	3 Months Ended
	Mar. 31, 2016
Capital Transactions
Capital Transactions	Capital Transactions Dividends The declaration of future dividends is subject to the discretion of the Company’s Board of Directors and will depend upon various factors, including the Company’s earnings, financial condition, restrictions imposed by any indebtedness that may be outstanding, cash requirements, future prospects and other factors deemed relevant by its Board of Directors. On February 25, 2016, the Company announced a cash dividend of $0.10 per common share in an aggregate amount of $1.9 million , which was paid on March 22, 2016 to shareholders of record as of March 11, 2016. Share Repurchase Program In November 2014, the Board of Directors authorized a $20.0 million share repurchase program beginning January 1, 2015. Such purchases may be made in the open market, through block trades, in privately negotiated transactions or otherwise. The timing and amount of any shares repurchased will be determined based on the Company’s evaluation of market conditions and other factors and the program may be discontinued or suspended at any time. At March 31, 2016 , the remaining balance available for repurchases under the program was $13.4 million . There were no repurchases of common shares by the Company during the three months ended March 31, 2016 . Share-Based Compensation During the year ended December 31, 2012, the Company’s shareholders adopted and approved the Nature’s Sunshine Products, Inc. 2012 Stock Incentive Plan (the “2012 Incentive Plan”). The 2012 Incentive Plan provides for the grant of incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock, restricted stock units, dividend equivalent rights, performance awards, stock awards and other stock-based awards. The Compensation Committee of the Board of Directors has authority and discretion to determine the type of award, as well as the amount, terms and conditions of each award under the 2012 Incentive Plan, subject to the limitations of the 2012 Incentive Plan. A total of 1,500,000 shares of the Company’s common stock were originally authorized for the granting of awards under the 2012 Incentive Plan. During the three-month period ended March 31, 2015, the Company’s shareholders approved an amendment to the 2012 Incentive Plan, to increase the number of shares of Common Stock reserved for issuance by 1,500,000 shares. The number of shares available for awards, as well as the terms of outstanding awards, are subject to adjustment as provided in the 2012 Incentive Plan for stock splits, stock dividends, recapitalizations and other similar events. The Company also maintains a stock incentive plan, which was approved by shareholders in 2009 (the “2009 Incentive Plan”). The 2009 Incentive Plan also provided for the grant of incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock, restricted stock units, dividend equivalent rights, performance awards, stock awards and other stock-based awards. Under the 2012 Incentive Plan, any shares subject to award, or awards forfeited or reacquired by the Company issued under the 2009 Incentive Plan are available for award up to a maximum of 400,000 shares. Stock Options The Company’s outstanding stock options include time-based stock options, which vest over differing periods ranging from the date of issuance up to 48 months from the option grant date; performance-based stock options, which have already vested upon achieving operating income margins of six , eight and ten percent as reported in four of five consecutive quarters over the term of the options; performance-based stock options, which vest upon achieving cumulative annual net sales revenue growth targets over a rolling two -year period, subject to the Company maintaining at least an eight percent operating income margin during the applicable period; and performance-based stock options, which vest upon achieving annual net sales targets over a rolling one -year period. Stock option activity for the three-month period ended March 31, 2016 , is as follows (amounts in thousands, except per share information): Number of Shares Weighted Average Exercise Price Per Share Options outstanding at December 31, 2015 1,683 $ 12.21 Granted — — Forfeited or canceled (50 ) 11.72 Exercised (25 ) 2.35 Options outstanding at March 31, 2016 1,608 12.38 Share-based compensation expense from time-based stock options for the three -month periods ended March 31, 2016 and 2015 , was approximately $0.3 million and $0.6 million , respectively. As of March 31, 2016 and December 31, 2015 , the unrecognized share-based compensation expense related to the grants described above was $0.8 million and $1.1 million , respectively. As of March 31, 2016 , the remaining compensation cost is expected to be recognized over the weighted-average period of approximately 1.5 years . The Company has not recognized any share-based compensation expense related to the net sales revenue performance-based stock options for the three-month periods ended March 31, 2016 and 2015 . Should the Company attain all of the net sales revenue metrics related to the net sales revenue performance-based stock option grants, the Company would recognize up to $0.4 million of potential share-based compensation expense. At March 31, 2016 , the aggregate intrinsic value of outstanding stock options to purchase 1,608,000 shares of common stock, exercisable stock options to purchase 1,143,000 shares of common stock and stock options to purchase 384,000 shares of common stock that are expected to vest was $0.7 million , $0.7 million and $0.0 million , respectively. At December 31, 2015 , the aggregate intrinsic value of outstanding options to purchase 1,683,000 shares of common stock, the exercisable options to purchase 958,000 shares of common stock, and options to purchase 588,000 shares of common stock expected to vest was $0.9 million , $0.9 million and $0.0 million , respectively. For the three -month periods ended March 31, 2016 and 2015 , the Company issued 25,000 and 227,000 shares of common stock upon the exercise of stock options at an average exercise price of $2.35 , and $7.63 per share, respectively. The aggregate intrinsic values of options exercised during the three -month periods ended March 31, 2016 and 2015 was $0.2 million , and $1.3 million , respectively. For the three -month periods ended March 31, 2016 and 2015 , the Company recognized $0.1 million and $0.6 million of tax benefits from the exercise of stock options during the period, respectively. Restricted Stock Units The Company’s outstanding restricted stock units ("RSUs") include time-based RSUs, which vest over differing periods ranging from 12 months up to 48 months from the RSU grant date. RSUs granted to the Board of Directors contain a restriction period in which the shares are not issued until two years after vesting. At March 31, 2016 and December 31, 2015 , there were 59,000 and 60,000 vested RSUs granted to the Board of Directors that had a restriction period. RSU activity for the three-month period ended March 31, 2016 , is as follows (amounts in thousands, except per share information): Number of Shares Weighted Average Grant Date Fair Value Restricted Stock Units outstanding at December 31, 2015 744 $ 12.48 Granted 167 8.73 Forfeited (2 ) 13.45 Issued (125 ) 13.17 Restricted Stock Units outstanding at March 31, 2016 784 11.53 During the three-month period ended March 31, 2016 , the Company granted 167,000 RSUs under the 2012 Incentive Plan to the Company’s Board of Directors, executive officers and other employees, which are composed of both time-based RSUs and net sales and operating income and earnings-per-share performance-based RSUs. The time-based RSUs were issued with a weighted-average grant date fair value of $9.08 per share and vest in annual installments over a three -year period from the grant date. The net sales and operating income and earnings-per-share performance-based RSUs were issued with a weighted-average grant date fair value of $8.16 per share and vest upon achieving both (i) net sales and operating income targets over a three -year period from the grant date and (ii) earnings-per-share targets over a six -year period from the grant date. RSUs are valued at market value on the date of grant, which is the grant date share price discounted for expected dividend payments during the vesting period. Share-based compensation expense from RSUs for the three-month periods ended March 31, 2016 and 2015 , was approximately $0.6 million and $0.8 million , respectively. As of March 31, 2016 and December 31, 2015 , the unrecognized share-based compensation expense related to the grants described above was $2.8 million and $2.5 million , respectively. As of March 31, 2016 , the remaining compensation expense is expected to be recognized over the weighted average period of approximately 1.8 years . The Company has not recognized any share-based compensation expense related to the net sales revenue and earnings-per-share performance-based RSUs for the three-month periods ended March 31, 2016 and 2015 . Should the Company attain all of the net sales revenue metrics related to the net sales revenue performance-based stock option grants, the Company would recognize up to $3.3 million of potential share-based compensation expense. The number of shares issued upon vesting of RSUs granted pursuant to the Company's share-based compensation plans is net of the minimum statutory withholding requirements that the Company pays on behalf of its employees, which was 20,000 shares for the three-month period ended March 31, 2016 . Although shares withheld are not issued, they are treated as common share repurchases for accounting purposes, as they reduce the number of shares that would have been issued upon vesting. These shares do not count against the authorized capacity under the repurchase program described above. Stock Appreciation Rights The Company’s outstanding stock appreciation rights ("SARs") are time-based SARs, which vest over differing periods ranging from 12 months up to 48 months from the SAR grant date. The SARs have a strike price equal to the fair market value of one share of common stock on the grant date. Subsequent to vesting, the employee has the option to exercise the SAR and will receive the intrinsic value of the SAR as income on the exercise date. SARs do not entitle a participant to receive or purchase shares and are settled in cash. SARs will not reduce the number of shares of common stock available for issuance under the Company’s Stock Incentive Plans. SAR activity for the three-month period ended March 31, 2016 , is as follows (amounts in thousands, except per share information): Number of Shares Weighted Average Grant Date Fair Value Stock Appreciation Rights outstanding at December 31, 2015 20 $ 5.27 Granted — — Forfeited or canceled — — Exercised — — Stock Appreciation Rights outstanding at March 31, 2016 20 5.27 Share-based compensation expense from SARs for the three-month period ended March 31, 2016 and 2015, was approximately $1,000 and $3,000 , respectively. As of March 31, 2016 and December 31, 2015 , the unrecognized share-based compensation expense related to the grants described above was $17,000 and $32,000 , respectively. As of March 31, 2016 , the remaining compensation expense is expected to be recognized over the weighted average period of approximately 1.9 years.

Segment Information

Segment Information	3 Months Ended
	Mar. 31, 2016
Segment Reporting [Abstract]
Segment Information	Segment Information The Company has four business segments. These business segments are components of the Company for which separate information is available that is evaluated regularly by the chief executive officer in deciding how to allocate resources and in assessing relative performance. The Company's four business segments are divided based on the different characteristics of their distributor bases, selling and distributor compensation plans and product formulations, as well as the internal organization of its officers and their responsibilities and business operations. Three business segments operate under the Nature’s Sunshine Products brand (NSP Americas; NSP Russia, Central and Eastern Europe; and China and New Markets). The Company’s China and New Markets segment anticipates deploying a multi-channel go-to-market strategy that offers select Nature’s Sunshine branded products through a direct selling model across China as well as through e-commerce channels. The time to market will be dependent upon regulatory processes including product registration and permit approvals. The China and New Markets segment also includes the Company’s wholesale business, in which the Company sells its products to various locally managed entities independent of the Company that have distribution rights for the relevant market. All of the net sales revenue to date in the China and New Markets segment is through the Company’s wholesale business to foreign markets outside of China detailed below. The fourth business segment operates under the Synergy® WorldWide brand. Reportable business segment information is as follows (dollar amounts in thousands): Three Months Ended 2016 2015 Net sales revenue: NSP Americas $ 45,183 $ 46,510 NSP Russia, Central and Eastern Europe 6,352 7,443 Synergy WorldWide 29,848 28,768 China and New Markets 1,019 1,157 Total net sales revenue 82,402 83,878 Contribution margin (1): NSP Americas 18,917 19,520 NSP Russia, Central and Eastern Europe 2,181 2,596 Synergy WorldWide 8,939 9,048 China and New Markets 468 496 Total contribution margin 30,505 31,660 Selling, general and administrative 28,385 26,330 Operating income 2,120 5,330 Other income (expense), net 1,559 (318 ) Income from continuing operations before provision for income taxes $ 3,679 $ 5,012 _________________________________________ (1) Contribution margin consists of net sales revenue less cost of sales and volume incentives expense. From an individual country perspective, only the United States and South Korea comprise 10 percent or more of consolidated net sales revenue for the three-month periods ended March 31, 2016 and 2015 , as follows (dollar amounts in thousands): Three Months Ended 2016 2015 Net sales revenue: United States $ 38,295 $ 38,522 South Korea 13,198 12,080 Other 30,909 33,276 $ 82,402 $ 83,878 Revenue generated by each of the Company’s product lines is set forth below (dollar amounts in thousands): Three Months Ended 2016 2015 NSP Americas: General health $ 19,617 $ 20,032 Immune 5,576 6,217 Cardiovascular 3,112 3,101 Digestive 13,079 13,365 Personal care 930 970 Weight management 2,869 2,825 45,183 46,510 NSP Russia, Eastern and Central Europe: General health $ 2,723 $ 2,879 Immune 540 913 Cardiovascular 477 453 Digestive 2,121 1,970 Personal care 249 882 Weight management 242 346 6,352 7,443 Synergy WorldWide: General health $ 8,640 $ 7,702 Immune 209 193 Cardiovascular 12,693 12,655 Digestive 2,487 2,294 Personal care 1,939 1,830 Weight management 3,880 4,094 29,848 28,768 China and New Markets: General health $ 471 $ 531 Immune 131 158 Cardiovascular 73 81 Digestive 260 290 Personal care 22 27 Weight management 62 70 1,019 1,157 $ 82,402 $ 83,878 Beginning in 2016, for the Synergy WorldWide segment, the Company changed its allocation of products sold within promotional product kits from the category associated with the predominant product, to each individual product being included in its respective category. Prior periods have been reclassified to conform to the current period’s presentation. From an individual country perspective, only the United States comprised 10 percent or more of consolidated property, plant and equipment as follows (dollar amounts in thousands): March 31, December 31, Property, plant and equipment: United States $ 66,949 $ 66,044 Other 2,425 2,684 Total property, plant and equipment $ 69,374 $ 68,728

Income Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2016
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes For the three months ended March 31, 2016 and 2015 , the Company’s provision for income taxes, as a percentage of income before income taxes was 51.4 percent and 16.1 percent , respectively, compared with a U.S. federal statutory rate of 35.0 percent . The difference between the effective tax rate and the U.S. federal statutory tax rate for the three months ended March 31, 2016 , was primarily attributed to current year foreign losses, primarily related to China, that presently do not provide future tax benefit and an adjustment of a prior year deferred tax asset related to foreign currency translation amounts offset by net favorable foreign items related to tax rate differences. The difference between the effective tax rate and the U.S. federal statutory tax rate for the three months ended March 31, 2015 was primarily attributed to the partial utilization of discrete foreign tax credit benefits related to intercompany dividends paid by foreign subsidiaries to the U.S. corporation in prior years. Changes to the effective rate due to dividends received from foreign subsidiaries and the impact of foreign tax credits are expected to be recurring. Depending on various factors, changes from the foregoing items may be favorable or unfavorable in a particular period. The Company’s U.S. federal income tax returns for 2012 through 2014 are open to examination for federal tax purposes. The Company has several foreign tax jurisdictions that have open tax years from 2008 through 2015. As of March 31, 2016 and December 31, 2015 , the Company had accrued $7.8 million related to unrecognized tax positions. Interim income taxes are based on an estimated annualized effective tax rate applied to the respective quarterly periods, adjusted for discrete tax items in the period in which they occur. Although the Company believes its tax estimates are reasonable, the Company can make no assurance that the final tax outcome of these matters will not be different from that which it has reflected in its historical income tax provisions and accruals. Such differences could have a material impact on the Company’s income tax provision and operating results in the period in which the Company makes such determination.

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2016
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Legal Proceedings The Company is party to various legal proceedings. Management cannot predict the ultimate outcome of these proceedings, individually or in the aggregate, or their resulting effect on the Company’s business, financial position, results of operations or cash flows as litigation and related matters are subject to inherent uncertainties, and unfavorable rulings could occur. Were an unfavorable outcome to occur, there exists the possibility of a material adverse impact on the business, financial position, results of operations, or cash flows for the period in which the ruling occurs and/or future periods. The Company maintains product liability, general liability and excess liability insurance coverage. However, no assurances can be given that such insurance will continue to be available at an acceptable cost to the Company, that such coverage will be sufficient to cover one or more large claims, or that the insurers will not successfully disclaim coverage as to a pending or future claim. Non-Income Tax Contingencies The Company has reserved for certain state sales and use tax and foreign non-income tax contingencies based on the likelihood of an obligation in accordance with accounting guidance for probable loss contingencies. Loss contingency provisions are recorded for probable losses at management’s best estimate of a loss, or when a best estimate cannot be made, a minimum loss contingency amount is recorded. The Company provides provisions for potential payments of tax to various tax authorities for contingencies related to non-income tax matters, including value-added taxes and sales tax. The Company provides provisions for U.S. state sales taxes in each of the states where the Company has nexus. As of March 31, 2016 and December 31, 2015 , accrued liabilities were $0.3 million related to non-income tax contingencies. While management believes that the assumptions and estimates used to determine this liability are reasonable, the ultimate outcome of those matters cannot presently be determined. The Company believes future payments related to these matters could range from $0 to approximately $3.6 million . Other Litigation The Company is party to various other legal proceedings in several foreign jurisdictions related to value-added tax assessments and other civil litigation. While there is a reasonable possibility that a loss may be incurred, either the losses are not considered to be probable or the Company cannot at this time estimate the loss, if any; therefore, no provision for losses has been provided. The Company believes future payments related to these matters could range from $0 to approximately $0.1 million .

Fair Value Measurements

Fair Value Measurements	3 Months Ended
	Mar. 31, 2016
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements The fair value of a financial instrument is the amount that could be received upon the sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Financial assets are marked to bid prices and financial liabilities are marked to offer prices. Fair value measurements do not include transaction costs. A fair value hierarchy is used to prioritize the quality and reliability of the information used to determine fair values of each financial instrument. Categorization within the fair value hierarchy is based on the lowest level of input that is significant to the fair value measurement. The fair value hierarchy is defined into the following three categories: Level 1: Quoted market prices in active markets for identical assets or liabilities. Level 2: Observable market based inputs or unobservable inputs that are corroborated by market data. Level 3: Unobservable inputs that are not corroborated by market data. The following table presents the Company’s hierarchy for its assets, measured at fair value on a recurring basis, as of March 31, 2016 (dollar amounts in thousands): Level 1 Level 2 Level 3 Quoted Prices in Active Markets for Identical Assets Significant Other Observable Inputs Significant Unobservable Inputs Total Investments available-for-sale U.S. government security funds $ 1,791 $ — $ — $ 1,791 Investment securities 1,199 — — 1,199 Total assets measured at fair value on a recurring basis $ 2,990 $ — $ — $ 2,990 The following table presents the Company’s hierarchy for its assets, measured at fair value on a recurring basis, as of December 31, 2015 (dollar amounts in thousands): Level 1 Level 2 Level 3 Quoted Prices in Active Markets for Identical Assets Significant Other Observable Inputs Significant Unobservable Inputs Total Investments available-for-sale U.S. government security funds $ 1,772 $ — $ — $ 1,772 Investment securities 1,044 — — 1,044 Total assets measured at fair value on a recurring basis $ 2,816 $ — $ — $ 2,816 Investments available-for-sale — The majority of the Company’s investment portfolio consist of various securities such as state and municipal obligations, U.S. government security funds, short-term deposits and various equity securities. The Level 1 securities are valued using quoted prices for identical assets in active markets including equity securities and U.S. government treasuries. Investment securities — The Company’s trading portfolio consists of various marketable securities that are valued using quoted prices in active markets. For the three months ended March 31, 2016 , and for the year ended December 31, 2015 , there were no fair value measurements using the significant unobservable inputs (Level 3). The carrying amounts reflected on the condensed consolidated balance sheet for cash and cash equivalents, accounts receivable, accounts payable and the revolving credit facility payable approximate fair value due to their short-term nature. During the three months ended March 31, 2016 and 2015 , the Company did not have any re-measurements of non-financial assets at fair value on a nonrecurring basis subsequent to their initial recognition.

Basis of Presentation (Policies

Basis of Presentation (Policies)	3 Months Ended
	Mar. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	Basis of Presentation Nature’s Sunshine Products, Inc., together with its subsidiaries (hereinafter referred to collectively as the “Company”), is a natural health and wellness company primarily engaged in the manufacturing and direct selling of nutritional and personal care products. The Company is a Utah corporation with its principal place of business in Lehi, Utah, and sells its products to a sales force of independent Managers and Distributors who use the products themselves or resell them to other independent Distributors or consumers. The formulation, manufacturing, packaging, labeling, advertising, distribution and sale of each of the Company’s major product groups are subject to regulation by one or more governmental agencies. The Company markets its products in Australia, Austria, Belarus, Canada, Colombia, Costa Rica, the Czech Republic, Denmark, the Dominican Republic, Ecuador, El Salvador, Finland, Germany, Guatemala, Honduras, Hong Kong, Iceland, Indonesia, Ireland, Italy, Japan, Kazakhstan, Latvia, Lithuania, Malaysia, Mexico, Moldova, Mongolia, the Netherlands, New Zealand, Nicaragua, Norway, Panama, the Philippines, Poland, Russia, Singapore, Slovenia, South Korea, Spain, Sweden, Taiwan, Thailand, Ukraine, the United Kingdom, and the United States. The Company also markets its products through a wholesale model to Argentina, Australia, Chile, Israel, New Zealand, Norway, Peru, Portugal, Spain and the United Kingdom.
Principles of Consolidation	Principles of Consolidation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. The unaudited condensed consolidated financial statements include the accounts of the Company and its subsidiaries. All significant intercompany accounts and transactions are eliminated in consolidation. In the opinion of management, the accompanying unaudited condensed consolidated financial statements contain all adjustments (consisting of normal recurring accruals), considered necessary for a fair presentation of the Company’s financial information as of March 31, 2016 , and for the three-month periods ended March 31, 2016 and 2015 . The results of operations of any interim period are not necessarily indicative of the results of operations to be expected for the fiscal year ending December 31, 2016 . It is suggested that these condensed consolidated financial statements be read in conjunction with the consolidated financial statements and the notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2015 .
Classification of Belarus as a Highly Inflationary Economy and Devaluation of Its Currency	Classification of Belarus as a Highly Inflationary Economy and Devaluation of Its Currency Since June 30, 2012, Belarus has been designated as a highly inflationary economy. The U.S. dollar is the Company’s functional currency for this market. As a result, there were no resulting gains or losses from a re-measurement of the financial statements using official rates of the Company’s Belarusian subsidiary. However, as a result of the weakening of the Belarusian ruble, the purchasing power of the Company’s independent Distributors in this market is reduced. During the three months ended March 31, 2016 and 2015 , the Company’s Belarusian subsidiary’s net sales revenue represented approximately 1.6 percent and 2.1 percent of consolidated net sales revenue, respectively.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09 Revenue from Contracts with Customers (Topic 606). This update requires an entity to recognize revenue to depict the transfer of promised goods and services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods and services. As such, this update affects an entity that either enters into contracts with customers or transfers goods and services or enters into contracts for the transfer of nonfinancial assets unless those contracts are within the scope of other standards. This update will supersede the revenue recognition requirements in Topic 605, Revenue Recognition, and most industry-specific guidance, and creates a Topic 606. In March 2016, the FASB issued ASU 2016-08, Revenue from Contracts with Customers - Principal versus Agent Considerations (Reporting Revenue Gross versus Net) , which further clarifies the implementation guidance on principal versus agent considerations contained in ASU 2014-09. In April 2016, the FASB issued ASU 2016-08, Revenue from Contracts with Customers - Identifying Performance Obligations and Licensing , which further clarifies the implementation guidance relating to identifying performance obligations and the licensing implementation guidance. These standards, pursuant to ASU No. 2015-14, Revenue from Contracts with Customers - Deferral of the Effective Date issued by the FASB in August 2015, will be effective for the Company in the first quarter of 2018. The adoption of this ASU is not expected to have a material impact on the Company’s results of operations, consolidated financial statements and footnote disclosures.” In August 2014, the FASB issued ASU No. 2014-15, Presentation of Financial Statements: "Going Concern" (Subtopic 205-40). The purpose of this ASU is to incorporate into U.S. GAAP management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern within one year after the date that the financial statements are issued, and to provide related footnote disclosures. This update is effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early application is permitted. The adoption of this ASU is not expected to have a material impact on the Company’s results of operations, consolidated financial statements and footnote disclosures. In July 2015, the FASB issued ASU No. 2015-11, Inventory (Topic 330): “Simplifying the Measurement of Inventory.” This update specifies that inventory should be subsequently measured at the lower of cost or net realizable value, which is the ordinary selling price less any completion, transportation and disposal costs. However, the ASU does not apply to inventory measured using the last-in-first-out or retail methods. This update is effective for interim and annual periods beginning after December 15, 2016. Adoption of the ASU is prospective. The adoption of this ASU is not expected to have a material impact on the Company’s results of operations, consolidated financial statements and footnote disclosures. In November 2015, the FASB issued ASU 2015-17, Income Taxes (Topic 740): "Balance Sheet Classification of Deferred Taxes." This guidance requires that entities with a classified statement of financial position present all deferred tax assets and liabilities as noncurrent. This update is effective for annual and interim periods for fiscal years beginning after December 15, 2016, which will require the Company to adopt the new guidance in the first quarter of fiscal 2017. Early adoption is permitted for financial statements that have not been previously issued and may be applied on either a prospective or retrospective basis. The adoption of this ASU is not expected to have a material impact on the Company’s results of operations, consolidated financial statements and footnote disclosures. In January 2016, the FASB issued ASU No. 2016-01, Financial Instruments - Overall (Subtopic 825-10): "Recognition and Measurement of Financial Assets and Financial Liabilities." This update amends the guidance in U.S. GAAP on the classification and measurement of financial instruments. Although the ASU retains many current requirements, it significantly revises an entity’s accounting related to (1) the classification and measurement of investments in equity securities and (2) the presentation of certain fair value changes for financial liabilities measured at fair value. The ASU also amends certain disclosure requirements associated with the fair value of financial instruments. This update is effective for interim and annual periods beginning after December 15, 2017. The adoption of this ASU is not expected to have a material impact on the Company’s results of operations, consolidated financial statements and footnote disclosures. In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842): "Accounting for Leases." This update specifies that lessees should recognize assets and liabilities arising from all leases, except for leases with a lease term of 12 months or less. The recognition, measurement, and presentation of expenses and cash flows arising from a lease by a lessee will largely remain unchanged and continue to depend on its classification as a finance or operating lease. For public companies, the ASU will be effective for annual periods beginning after December 15, 2018 with early adoption permitted. The adoption of this ASU is not expected to have a material impact on the Company’s results of operations or footnote disclosures; however, it is expected to gross-up the consolidated balance sheet. In March 2016, the FASB issued ASU 2016-09, Compensation - Stock Compensation (Topic 718): "Improvements to Employee Share-Based Payment Accounting". The amendments are effective for public companies for annual periods beginning after December 15, 2016, and interim periods within those annual periods. Several aspects of the accounting for share-based payment award transactions are simplified, including: (a) income tax consequences; (b) classification of awards as either equity or liabilities; and (c) classification on the statement of cash flows. The Company is currently in the process of evaluating the impact of the adoption on its financial statements.

Discontinued Operations (Tables

Discontinued Operations (Tables)	3 Months Ended
	Mar. 31, 2016
Discontinued Operations and Disposal Groups [Abstract]
Schedule of operating results of the entity's discontinued operations	The following table summarizes the operating results of the Company’s discontinued operations (dollar amounts in thousands): March 31, March 31, Net sales revenue $ — $ — Income before income tax provision $ — $ 1,312 Income tax provision — — Income from discontinued operations $ — $ 1,312

Inventories (Tables)

Inventories (Tables)	3 Months Ended
	Mar. 31, 2016
Inventory Disclosure [Abstract]
Schedule of composition of inventories	The composition of inventories is as follows (dollar amounts in thousands): March 31, December 31, Raw materials $ 14,183 $ 13,351 Work in progress 758 789 Finished goods 26,629 24,355 Total inventory $ 41,570 $ 38,495

Investments (Tables)

Investments (Tables)	3 Months Ended
	Mar. 31, 2016
Investments, Debt and Equity Securities [Abstract]
Schedule of amortized cost and estimated fair values of available-for-sale securities by balance sheet classification	The amortized cost and estimated fair values of available-for-sale securities by balance sheet classification are as follows (dollar amounts in thousands): As of March 31, 2016 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value U.S. government securities funds $ 1,794 $ — $ (3 ) $ 1,791 Total short-term investment securities $ 1,794 $ — $ (3 ) $ 1,791 As of December 31, 2015 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value U.S. government securities funds $ 1,794 $ — $ (22 ) $ 1,772 Total short-term investment securities $ 1,794 $ — $ (22 ) $ 1,772

Net Income Per Share (Tables)

Net Income Per Share (Tables)	3 Months Ended
	Mar. 31, 2016
Earnings Per Share [Abstract]
Schedule of reconciliation of the numerator and denominator of Basic EPS to the numerator and denominator of Diluted EPS	Following is a reconciliation of the numerator and denominator of Basic EPS to the numerator and denominator of Diluted EPS for the three months ended March 31, 2016 and 2015 (dollar and share amounts in thousands, except for per share information): Three Months Ended 2016 2015 Net income attributable to common shareholders: Net income from continued operations $ 2,069 $ 4,355 Income from discontinued operations $ — $ 1,312 Net income $ 2,069 $ 5,667 Basic weighted average shares outstanding 18,694 18,621 Basic earnings per share attributable to common shareholders: Net income from continued operations $ 0.11 $ 0.23 Income from discontinued operations $ — $ 0.07 Net income $ 0.11 $ 0.30 Diluted shares outstanding Basic weighted-average shares outstanding 18,694 18,621 Stock-based awards 436 571 Diluted weighted-average shares outstanding 19,130 19,192 Diluted earnings per share attributable to common shareholders: Net income from continued operations $ 0.11 $ 0.23 Income from discontinued operations $ — $ 0.07 Net income $ 0.11 $ 0.30 Potentially dilutive shares excluded from diluted-per-share amounts: Stock options 86 399 Potentially anti-dilutive shares excluded from diluted-per-share amounts: Stock options 1,454 733

Capital Transactions (Tables)

Capital Transactions (Tables)	3 Months Ended
	Mar. 31, 2016
Capital Transactions
Schedule of stock option activity	Stock option activity for the three-month period ended March 31, 2016 , is as follows (amounts in thousands, except per share information): Number of Shares Weighted Average Exercise Price Per Share Options outstanding at December 31, 2015 1,683 $ 12.21 Granted — — Forfeited or canceled (50 ) 11.72 Exercised (25 ) 2.35 Options outstanding at March 31, 2016 1,608 12.38
Schedule of restricted stock unit activity	RSU activity for the three-month period ended March 31, 2016 , is as follows (amounts in thousands, except per share information): Number of Shares Weighted Average Grant Date Fair Value Restricted Stock Units outstanding at December 31, 2015 744 $ 12.48 Granted 167 8.73 Forfeited (2 ) 13.45 Issued (125 ) 13.17 Restricted Stock Units outstanding at March 31, 2016 784 11.53
Schedule of stock appreciation right activity	SAR activity for the three-month period ended March 31, 2016 , is as follows (amounts in thousands, except per share information): Number of Shares Weighted Average Grant Date Fair Value Stock Appreciation Rights outstanding at December 31, 2015 20 $ 5.27 Granted — — Forfeited or canceled — — Exercised — — Stock Appreciation Rights outstanding at March 31, 2016 20 5.27

Segment Information (Tables)

Segment Information (Tables)	3 Months Ended
	Mar. 31, 2016
Segment Reporting [Abstract]
Schedule of reportable business segment information	Reportable business segment information is as follows (dollar amounts in thousands): Three Months Ended 2016 2015 Net sales revenue: NSP Americas $ 45,183 $ 46,510 NSP Russia, Central and Eastern Europe 6,352 7,443 Synergy WorldWide 29,848 28,768 China and New Markets 1,019 1,157 Total net sales revenue 82,402 83,878 Contribution margin (1): NSP Americas 18,917 19,520 NSP Russia, Central and Eastern Europe 2,181 2,596 Synergy WorldWide 8,939 9,048 China and New Markets 468 496 Total contribution margin 30,505 31,660 Selling, general and administrative 28,385 26,330 Operating income 2,120 5,330 Other income (expense), net 1,559 (318 ) Income from continuing operations before provision for income taxes $ 3,679 $ 5,012 _________________________________________ (1) Contribution margin consists of net sales revenue less cost of sales and volume incentives expense.
Schedule of consolidated net sales revenue by geographical locations	From an individual country perspective, only the United States and South Korea comprise 10 percent or more of consolidated net sales revenue for the three-month periods ended March 31, 2016 and 2015 , as follows (dollar amounts in thousands): Three Months Ended 2016 2015 Net sales revenue: United States $ 38,295 $ 38,522 South Korea 13,198 12,080 Other 30,909 33,276 $ 82,402 $ 83,878
Schedule of revenue generated by each of the Company's product lines	Revenue generated by each of the Company’s product lines is set forth below (dollar amounts in thousands): Three Months Ended 2016 2015 NSP Americas: General health $ 19,617 $ 20,032 Immune 5,576 6,217 Cardiovascular 3,112 3,101 Digestive 13,079 13,365 Personal care 930 970 Weight management 2,869 2,825 45,183 46,510 NSP Russia, Eastern and Central Europe: General health $ 2,723 $ 2,879 Immune 540 913 Cardiovascular 477 453 Digestive 2,121 1,970 Personal care 249 882 Weight management 242 346 6,352 7,443 Synergy WorldWide: General health $ 8,640 $ 7,702 Immune 209 193 Cardiovascular 12,693 12,655 Digestive 2,487 2,294 Personal care 1,939 1,830 Weight management 3,880 4,094 29,848 28,768 China and New Markets: General health $ 471 $ 531 Immune 131 158 Cardiovascular 73 81 Digestive 260 290 Personal care 22 27 Weight management 62 70 1,019 1,157 $ 82,402 $ 83,878
Schedule of consolidated property, plant and equipment by geographical locations	From an individual country perspective, only the United States comprised 10 percent or more of consolidated property, plant and equipment as follows (dollar amounts in thousands): March 31, December 31, Property, plant and equipment: United States $ 66,949 $ 66,044 Other 2,425 2,684 Total property, plant and equipment $ 69,374 $ 68,728

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2016
Fair Value Disclosures [Abstract]
Schedule of the Company's hierarchy for assets measured at fair value on a recurring basis	The following table presents the Company’s hierarchy for its assets, measured at fair value on a recurring basis, as of March 31, 2016 (dollar amounts in thousands): Level 1 Level 2 Level 3 Quoted Prices in Active Markets for Identical Assets Significant Other Observable Inputs Significant Unobservable Inputs Total Investments available-for-sale U.S. government security funds $ 1,791 $ — $ — $ 1,791 Investment securities 1,199 — — 1,199 Total assets measured at fair value on a recurring basis $ 2,990 $ — $ — $ 2,990 The following table presents the Company’s hierarchy for its assets, measured at fair value on a recurring basis, as of December 31, 2015 (dollar amounts in thousands): Level 1 Level 2 Level 3 Quoted Prices in Active Markets for Identical Assets Significant Other Observable Inputs Significant Unobservable Inputs Total Investments available-for-sale U.S. government security funds $ 1,772 $ — $ — $ 1,772 Investment securities 1,044 — — 1,044 Total assets measured at fair value on a recurring basis $ 2,816 $ — $ — $ 2,816

Basis of Presentation (Details)

Basis of Presentation (Details) - Belarusian subsidiary - USD ($)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Classification of Venezuela and Belarus as a Highly Inflationary Economy and Devaluation of Its Currencies
Gains or losses from a re-measurement of the financial statements using official exchange rates	$ 0
Net sales revenue as a percent of consolidated net sales revenue	1.60%	2.10%

Basis of Presentation - Restruc

Basis of Presentation - Restructuring Related Activities (Details) - USD ($)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Dec. 31, 2015
Restructuring Cost and Reserve [Line Items]
Restructuring expenses	$ 0	$ 0
Severance costs
Restructuring Cost and Reserve [Line Items]
Restructuring reserve	100,000		$ 600,000
Other exit costs
Restructuring Cost and Reserve [Line Items]
Restructuring reserve	$ 100,000		$ 200,000

Discontinued Operations (Detail

Discontinued Operations (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Discontinued operations
Income (loss) from discontinued operations	$ 0	$ 1,312
Net proceeds from sale of fixed assets	14	1,312
Subsidiary in Venezuela
Discontinued operations
Net sales revenue	0	0
Income before income tax provision	0	1,312
Income tax provision	0	0
Income (loss) from discontinued operations	$ 0	1,312
Net proceeds from sale of fixed assets		$ 1,300

Inventories (Details)

Inventories (Details) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Inventory Disclosure [Abstract]
Raw materials	$ 14,183	$ 13,351
Work in progress	758	789
Finished goods	26,629	24,355
Total inventory	$ 41,570	$ 38,495

Investments (Details)

Investments (Details) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	$ 1,794	$ 1,794
Gross Unrealized Gains	0	0
Gross Unrealized Losses	(3)	(22)
Fair Value	1,791	1,772
U.S. government security funds
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	1,794	1,794
Gross Unrealized Gains	0	0
Gross Unrealized Losses	(3)	(22)
Fair Value	$ 1,791	$ 1,772

Investments (Details 2)

Investments (Details 2) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Dec. 31, 2015
Schedule of Available-for-sale Securities [Line Items]
Proceeds from the sales of available-for-sale securities	$ 0	$ 0
Trading securities portfolio	1,199,000		$ 1,044,000
Gains	7,000	$ 23,000
Securities in a loss position for more than 12 months	0		0
U.S. government security funds
Schedule of Available-for-sale Securities [Line Items]
Net Unrealized Losses	$ (3,000)		$ (22,000)

Revolving Credit Facility (Deta

Revolving Credit Facility (Details) - Revolving credit agreement - USD ($)	3 Months Ended
	Mar. 31, 2016	Dec. 31, 2015
Long-term debt
Maximum borrowing capacity	$ 25,000,000
Annual commitment fee	0.25%
Long-term debt less current installments	$ 7,500,000	$ 2,700,000
LIBOR
Long-term debt
Margin on variable rate	1.25%
Effective interest rate	1.75%	1.75%

Net Income Per Share (Details)

Net Income Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Net income attributable to common shareholders:
Net income from continued operations	$ 2,069	$ 4,355
Income from discontinued operations	0	1,312
Net income	$ 2,069	$ 5,667
Basic weighted-average shares outstanding (in shares)	18,694	18,621
Basic earnings per share attributable to common shareholders:
Net income from continued operations (in dollars per share)	$ 0.11	$ 0.23
Income (loss) from discontinued operations (in dollars per share)	0	0.07
Net income (in dollars per share)	$ 0.11	$ 0.30
Diluted shares outstanding
Basic weighted-average shares outstanding (in shares)	18,694	18,621
Stock-based awards (in shares)	436	571
Diluted weighted-average shares outstanding (in shares)	19,130	19,192
Diluted earnings per share attributable to common shareholders:
Net income from continued operations (in dollars per share)	$ 0.11	$ 0.23
Income from discontinued operations (in dollars per share)	0	0.07
Net income (in dollars per share)	$ 0.11	$ 0.30
Potentially dilutive shares excluded from diluted-per-share amounts:
Stock options (in shares)	86	399
Potentially anti-dilutive shares excluded from diluted-per-share amounts:
Stock options (in shares)	1,454	733

Capital Transactions (Details)

Capital Transactions (Details) - USD ($)	Feb. 25, 2016	Mar. 31, 2016	Mar. 31, 2015	Dec. 31, 2015	Nov. 30, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Cash dividend per common share (in dollars per share)	$ 0.10	$ 0.10	$ 0.10
Payments of cash dividends	$ 1,900,000	$ 1,872,000	$ 1,865,000
Tax benefit from the exercise of stock options		$ 0	52,000
Weighted Average Exercise Price Per Share
Granted (in dollars per share)		$ 0
Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercisable (in shares)		1,143,000		958,000
Expected to vest (in shares)		384,000		588,000
Aggregate Intrinsic value, outstanding		$ 700,000		$ 900,000
Aggregate Intrinsic value, exercisable		700,000		900,000
Aggregate intrinsic values of options exercised		200,000	1,300,000
Aggregate Intrinsic value, expected to vest		0		0
Tax benefit from the exercise of stock options		$ 100,000	$ 600,000
Number of shares
Options outstanding at the beginning of the period (in shares)		1,683,000
Granted (in shares)		0
Forfeited or canceled (in shares)		(50,000)
Exercised (in shares)		(25,000)	(227,000)
Options outstanding at the end of the period (in shares)		1,608,000
Weighted Average Exercise Price Per Share
Options outstanding at the beginning of the period (in dollars per share)		$ 12.21
Forfeited or canceled (in dollars per share)		11.72
Exercised (in dollars per share)		2.35	$ 7.63
Options outstanding at the end of the period (in dollars per share)		$ 12.38
Performance based stock options operating income margins
Share-based compensation, additional disclosures
Operating income margin, one (as a percent)		6.00%
Operating income margin, two (as a percent)		8.00%
Operating income margin, three (as a percent)		10.00%
Performance based stock options sales and operating income margins
Share-based compensation, additional disclosures
Vesting period		2 years
Performance based stock options sales and operating income margins | Minimum
Share-based compensation, additional disclosures
Operating income margin, two (as a percent)		8.00%
Performance based stock options sales
Share-based compensation, additional disclosures
Vesting period based on achieving annual net sales targets		1 year
Performance based stock options sales | Maximum
Share-based compensation, related information
Potential compensation expense		$ 400,000
Time-based stock options
Share-based compensation, related information
Share-based compensation expense		300,000	$ 600,000
Unrecognized share-based compensation expense		$ 800,000		$ 1,100,000
Weighted-average period over which the remaining compensation cost is expected to be recognized		1 year 6 months
Time-based stock options | Maximum
Share-based compensation, additional disclosures
Vesting period		48 months
2012 Stock Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized under the plan				1,500,000
Additional number of shares authorized under the plan			1,500,000
2009 Incentive Plan | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized under the plan		400,000
2014 Share Repurchase Program
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock repurchase program, authorized amount					$ 20,000,000
Remaining balance available for repurchases		$ 13,400,000
Repurchase of common stock (in shares)		0

Capital Transactions (Details 2

Capital Transactions (Details 2) - USD ($)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Dec. 31, 2015
RSUs
Share-based compensation, additional disclosures
Share-based compensation expense	$ 600,000	$ 800,000
Unrecognized share-based compensation expense	$ 2,800,000		$ 2,500,000
Weighted-average period over which the remaining compensation expense is expected to be recognized	1 year 9 months 18 days
Minimum statutory withholding requirement paid on behalf of employees (in shares)	20,000
Performance-based RSUs
Share-based compensation, additional disclosures
Share-based compensation expense	$ 0	0
Performance-based RSUs | Maximum
Share-based compensation, additional disclosures
Potential compensation expense	$ 3,300,000
2012 Stock Incentive Plan | RSUs
Number of Shares
Units outstanding at the beginning of the period (in shares)	744,000
Granted (in shares)	167,000
Forfeited (in shares)	(125,000)
Issued (in shares)	(2,000)
Units outstanding at the end of the period (in shares)	784,000
Weighted Average Grant Date Fair Value
Units outstanding at the beginning of the period (in dollars per share)	$ 12.48
Granted (in dollars per share)	8.73
Forfeited (in dollars per share)	13.17
Issued (in dollars per share)	13.45
Units outstanding at the end of the period (in dollars per share)	$ 11.53
2012 Stock Incentive Plan | RSUs | Minimum
Share-based compensation, additional disclosures
Vesting period	12 months
2012 Stock Incentive Plan | RSUs | Maximum
Share-based compensation, additional disclosures
Vesting period	48 months
2012 Stock Incentive Plan | RSUs | Board of Directors
Number of Shares
Number of shares subject to restriction period	59,000		60,000
Restriction period	2 years
2012 Stock Incentive Plan | Performance-based RSUs
Share-based compensation, additional disclosures
Weighted-average grant date fair value (in dollars per share)	$ 8.16
2012 Stock Incentive Plan | Time-based RSUs
Share-based compensation, additional disclosures
Vesting period	3 years
Weighted-average grant date fair value (in dollars per share)	$ 9.08
2012 Stock Incentive Plan | SARs
Number of Shares
Units outstanding at the beginning of the period (in shares)	20,000
Granted (in shares)	0
Forfeited (in shares)	0
Issued (in shares)	0
Units outstanding at the end of the period (in shares)	20,000
Weighted Average Grant Date Fair Value
Units outstanding at the beginning of the period (in dollars per share)	$ 5.27
Granted (in dollars per share)	0
Forfeited (in dollars per share)	0
Issued (in dollars per share)	0
Units outstanding at the end of the period (in dollars per share)	$ 5.27
Share-based compensation, additional disclosures
Number of shares of common stock used for determining the fair value, or strike price, of grants	1
Share-based compensation expense	$ 1,000	$ 3,000
Unrecognized share-based compensation expense	$ 0		$ 0
Weighted-average period over which the remaining compensation expense is expected to be recognized	1 year 10 months 24 days
2012 Stock Incentive Plan | SARs | Minimum
Share-based compensation, additional disclosures
Vesting period	12 months
2012 Stock Incentive Plan | SARs | Maximum
Share-based compensation, additional disclosures
Vesting period	48 months
2012 Stock Incentive Plan | Net Sales and Operating Income Targets [Member] | Performance-based RSUs
Share-based compensation, additional disclosures
Vesting period	3 years
2012 Stock Incentive Plan | Earnings Per Share Targets [Member] | Performance-based RSUs
Share-based compensation, additional disclosures
Vesting period	6 years

Segment Information (Details)

Segment Information (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2016USD ($)segment	Mar. 31, 2015USD ($)	Dec. 31, 2015USD ($)
Segment information
Number of business segments | segment	4
Number of operating segments | segment	3
Net sales revenue:
Total net sales revenue	$ 82,402	$ 83,878
Contribution margin:
Total contribution margin	30,505	31,660
Selling, general and administrative	28,385	26,330
Operating income	2,120	5,330
Other income (expense), net	1,559	(318)
Income from continuing operations before provision for income taxes	3,679	5,012
Property, plant and equipment
Total property, plant and equipment	69,374		$ 68,728
United States
Net sales revenue:
Total net sales revenue	38,295	38,522
Property, plant and equipment
Total property, plant and equipment	66,949		66,044
Other
Net sales revenue:
Total net sales revenue	30,909	33,276
Property, plant and equipment
Total property, plant and equipment	2,425		$ 2,684
South Korea (Synergy)
Net sales revenue:
Total net sales revenue	13,198	12,080
NSP Americas
Net sales revenue:
Total net sales revenue	45,183	46,510
Contribution margin:
Total contribution margin	18,917	19,520
NSP Americas | General health
Net sales revenue:
Total net sales revenue	19,617	20,032
NSP Americas | Immune
Net sales revenue:
Total net sales revenue	5,576	6,217
NSP Americas | Cardiovascular
Net sales revenue:
Total net sales revenue	3,112	3,101
NSP Americas | Digestive
Net sales revenue:
Total net sales revenue	13,079	13,365
NSP Americas | Personal care
Net sales revenue:
Total net sales revenue	930	970
NSP Americas | Weight management
Net sales revenue:
Total net sales revenue	2,869	2,825
NSP Russia, Central and Eastern Europe
Net sales revenue:
Total net sales revenue	6,352	7,443
Contribution margin:
Total contribution margin	2,181	2,596
NSP Russia, Central and Eastern Europe | General health
Net sales revenue:
Total net sales revenue	2,723	2,879
NSP Russia, Central and Eastern Europe | Immune
Net sales revenue:
Total net sales revenue	540	913
NSP Russia, Central and Eastern Europe | Cardiovascular
Net sales revenue:
Total net sales revenue	477	453
NSP Russia, Central and Eastern Europe | Digestive
Net sales revenue:
Total net sales revenue	2,121	1,970
NSP Russia, Central and Eastern Europe | Personal care
Net sales revenue:
Total net sales revenue	249	882
NSP Russia, Central and Eastern Europe | Weight management
Net sales revenue:
Total net sales revenue	242	346
Synergy WorldWide
Net sales revenue:
Total net sales revenue	29,848	28,768
Contribution margin:
Total contribution margin	8,939	9,048
Synergy WorldWide | General health
Net sales revenue:
Total net sales revenue	8,640	7,702
Synergy WorldWide | Immune
Net sales revenue:
Total net sales revenue	209	193
Synergy WorldWide | Cardiovascular
Net sales revenue:
Total net sales revenue	12,693	12,655
Synergy WorldWide | Digestive
Net sales revenue:
Total net sales revenue	2,487	2,294
Synergy WorldWide | Personal care
Net sales revenue:
Total net sales revenue	1,939	1,830
Synergy WorldWide | Weight management
Net sales revenue:
Total net sales revenue	3,880	4,094
China and New Markets
Net sales revenue:
Total net sales revenue	1,019	1,157
Contribution margin:
Total contribution margin	468	496
China and New Markets | General health
Net sales revenue:
Total net sales revenue	471	531
China and New Markets | Immune
Net sales revenue:
Total net sales revenue	131	158
China and New Markets | Cardiovascular
Net sales revenue:
Total net sales revenue	73	81
China and New Markets | Digestive
Net sales revenue:
Total net sales revenue	260	290
China and New Markets | Personal care
Net sales revenue:
Total net sales revenue	22	27
China and New Markets | Weight management
Net sales revenue:
Total net sales revenue	$ 62	$ 70

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Provision (benefit) for income taxes, as a percentage of income before income taxes	51.40%	16.10%
Statutory U.S. federal income tax rate	35.00%
Liability related to unrecognized tax benefits	$ 7,777		$ 7,809

Commitments and Contingencies (

Commitments and Contingencies (Details)	3 Months Ended
	Mar. 31, 2016USD ($)claim	Dec. 31, 2015USD ($)
Value-added tax assessments and other civil litigation
Commitments and contingencies
Minimum number of claims that the Company's insurance coverage may not be sufficient to cover | claim	1
Provision for losses	$ 0
Non-Income Tax Contingencies
Commitments and contingencies
Accrued liabilities	300,000	$ 300,000
Minimum | Value-added tax assessments and other civil litigation
Commitments and contingencies
Estimate of possible loss	0
Minimum | Non-Income Tax Contingencies
Commitments and contingencies
Estimate of possible loss		0
Maximum | Value-added tax assessments and other civil litigation
Commitments and contingencies
Estimate of possible loss	$ 133,000
Maximum | Non-Income Tax Contingencies
Commitments and contingencies
Estimate of possible loss		$ 3,555,000

Fair Value Measurements (Detail

Fair Value Measurements (Details) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Fair value
Investments available-for-sale	$ 1,791	$ 1,772
U.S. government security funds
Fair value
Investments available-for-sale	1,791	1,772
Recurring basis | Level 1 - Quoted Prices in Active Markets for Identical Assets
Fair value
Trading investment securities	1,199	1,044
Total assets measured at fair value on a recurring basis	2,990	2,816
Recurring basis | Level 1 - Quoted Prices in Active Markets for Identical Assets | U.S. government security funds
Fair value
Investments available-for-sale	1,791	1,772
Recurring basis | Level 2 - Significant Other Observable Inputs
Fair value
Trading investment securities	0	0
Total assets measured at fair value on a recurring basis	0	0
Recurring basis | Level 2 - Significant Other Observable Inputs | U.S. government security funds
Fair value
Investments available-for-sale	0	0
Recurring basis | Level 3 - Significant Unobservable Inputs
Fair value
Trading investment securities	0	0
Total assets measured at fair value on a recurring basis	0	0
Recurring basis | Level 3 - Significant Unobservable Inputs | U.S. government security funds
Fair value
Investments available-for-sale	0	0
Total | Recurring basis
Fair value
Trading investment securities	1,199	1,044
Total assets measured at fair value on a recurring basis	2,990	2,816
Total | Recurring basis | U.S. government security funds
Fair value
Investments available-for-sale	$ 1,791	$ 1,772